Skip to main content

Table 1 Baseline characteristics

From: Glycemic control among patients in China with type 2 diabetes mellitus receiving oral drugs or injectables

Characteristic Male Female All
  Mean±SD
Age, yrs 58.39±12.01 59.09±11.32 58.72±11.69
BMI, kg/m2 24.47±2.92 24.38±3.41 24.43±3.16
Duration of diabetes, yr 5.43±5.16 5.71±5.40 5.57±5.28
HbA1c, % 7.90±1.73 7.80±1.71 7.85±1.72
FPG, mmol/L 8.12±2.40 8.02±2.39 8.07±2.39
2hPPG, mmol/L 11.26±3.64 11.12±3.63 11.19±3.64
SBP, mmHg 132.35±14.79 131.39±15.50 131.89±15.14
DBP, mmHg 81.86±11.00 80.10±11.05 81.02±11.06
Triglycerides, mmol/L 2.22±1.65 2.10±1.46 2.16±1.56
Total cholesterol, mmol/L 4.71±1.48 4.75±1.48 4.73±1.48
LDL, mmol/L 2.92±1.16 2.92±1.16 2.92±1.16
Reason for insulin initiation, n (%)    
OAD ineffective 33341 (77.18) 29525 (78.17) 62866 (77.64)
Complication 5531 (12.80) 4862 (12.87) 10393 (12.84)
Patient requests 3041 (7.04) 2382 (6.31) 5423 (6.70)
Other reason 1288 (2.98) 1003 (2.65) 2291 (2.82)
Complications and comorbidities, n (%)    
Hypertension 41400 (33.25) 38194 (33.46) 79594 (33.35)
Coronary heart disease 12918 (10.38) 13125 (11.50) 26043 (10.91)
Dyslipidemia 25222 (20.26) 21712 (19.02) 46934 (19.67)
Cerebrovascular disease 6552 (5.26) 5526 (4.84) 12078 (5.06)
Diabetic retinopathy 9799 (7.87) 10046 (8.80) 19845 (8.32)
Diabetic neuropathy 13211 (10.61) 12930 (11.33) 26141 (10.95)
Diabetic nephropathy 7001 (5.62) 5702 (5.00) 12703 (5.32)
Diabetic foot 1380 (1.11) 1087 (0.95) 2467 (1.03)
Others 2438 (1.96) 2469 (2.16) 4907 (2.06)
  1. 2hPPG, 2-hr postprandial plasma glucose; BMI, body mass index; DBP, diastolic blood pressure; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin; LDL, low-density lipoprotein; SBP, systolic blood pressure; SD, standard deviation.